Effect of 5 alpha-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix (R)) vaporesection for treating benign prostatic hyperplasia
Purpose: Preoperative use of 5 alpha-reductase inhibitors (5ARIS) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH). Thus, we investigated the effects of preoperative 5ARI use in this setting. Materials and Met...
Gespeichert in:
| Veröffentlicht in: | Investigative and clinical urology 2020, 61(1), , pp.67-74 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 74 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Investigative and clinical urology |
| container_volume | 61 |
| creator | Chung, Jae Seung Seo, Won Ik Oh, Cheol Kyu Kim, Seong Cheol Park, Myung Chan Park, Sang Hyun Yu, Jihyeong Lee, Chan Ho Kim, Wansuk Park, Tae Yong Min, Kweon Sik Chung, Jae Il |
| description | Purpose: Preoperative use of 5 alpha-reductase inhibitors (5ARIS) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH). Thus, we investigated the effects of preoperative 5ARI use in this setting.
Materials and Methods: This retrospective study examined 184 patients who underwent thulium laser surgery for BPH during 2012-2017. Patients were grouped according to their 5ARI use in order to compare their preoperative and intraoperative characteristics and subsequent outcomes. Surgical efficiency was assessed using vaporesection efficiency. The total operation time, vaporesection time and prostate volume change were measured.
Results: The 5ARI+ group included 83 patients (45.1%) and the 5ARI- group included 101 patients (54.9%). There were no significant differences in the two groups' preoperative characteristics, postoperative prostate size, thulium laser energy use, or prostate volume reduction rate. However, relative to the 5ARI- group, the 5ARI+ group had a significant shorter total operative time (65.0 min vs. 70.0 min, p=0.013) and a significantly shorter vaporesection time (48.0 min vs. 54.0 min, p=0.014), which resulted in significantly higher vaporesection efficiency in the 5ARI+ group (0.66 mL/min vs. 0.51 mL/min, p |
| doi_str_mv | 10.4111/icu.2020.61.1.67 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_webof</sourceid><recordid>TN_cdi_pubmed_primary_31942465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a3b8f53478614e2484bbd7eaf6630440</doaj_id><sourcerecordid>31942465</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-634ce8203e7832923956a4dd1b3d51c8b5becebb35e4ed018d05377dff570bf3</originalsourceid><addsrcrecordid>eNqNUsGO0zAQjRCIXZW9c0I-UqEWO3achAPSqlqgUiWkVQ_cLNsZN95N7chxCv0dvhSnZSv2hi8zmnnvjT1-WfaW4CUjhHy0elzmOMdLTpZkycsX2XXOOF_ggv14-ZSzml5lN8PwgDEmnJaEVq-zK0pqlvrFdfb7zhjQEXmDCiS7vpWLAM2ooxwAWddaZaMPA_IOxRYQGGO1BaePEyO2Y2fH_adjjCHFhezGvXVTtpPBQUTv7-HgN_ZXSuZzdJC9DzCkcTbJGR9QDCCjdTukwNmdQ33wQ0wVjdpjD6Hv5GDlm-yVkd0AN3_jLNt-uduuvi0237-uV7ebhWY1jwtOmYYqxxTKiuZ1TuuCS9Y0RNGmILpShQINStECGDSYVA0uaFk2xhQlVobOsvlZ1gUjHrUVXtpT3HnxGMTt_XYtOCtrmlY6y9ZnbOPlg-iD3ctwPBFOBR92Qob0jA6EpKoyBWVlxQmDnFVMqaYEaTinmDGctD6ftfpR7aHR4GKQ3TPR5x1n23Sng-A14xVhSQCfBXTa3hDAXLgEi8kpIjlFTE4RnAgieJko7_6deSE8-SIBPpwBP0F5M5y-HC6w5KUCc5zneDrTOqr_R6_s9MPerfzoIv0DJlvetg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effect of 5 alpha-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix (R)) vaporesection for treating benign prostatic hyperplasia</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>KoreaMed Open Access</source><source>PubMed Central</source><creator>Chung, Jae Seung ; Seo, Won Ik ; Oh, Cheol Kyu ; Kim, Seong Cheol ; Park, Myung Chan ; Park, Sang Hyun ; Yu, Jihyeong ; Lee, Chan Ho ; Kim, Wansuk ; Park, Tae Yong ; Min, Kweon Sik ; Chung, Jae Il</creator><creatorcontrib>Chung, Jae Seung ; Seo, Won Ik ; Oh, Cheol Kyu ; Kim, Seong Cheol ; Park, Myung Chan ; Park, Sang Hyun ; Yu, Jihyeong ; Lee, Chan Ho ; Kim, Wansuk ; Park, Tae Yong ; Min, Kweon Sik ; Chung, Jae Il</creatorcontrib><description>Purpose: Preoperative use of 5 alpha-reductase inhibitors (5ARIS) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH). Thus, we investigated the effects of preoperative 5ARI use in this setting.
Materials and Methods: This retrospective study examined 184 patients who underwent thulium laser surgery for BPH during 2012-2017. Patients were grouped according to their 5ARI use in order to compare their preoperative and intraoperative characteristics and subsequent outcomes. Surgical efficiency was assessed using vaporesection efficiency. The total operation time, vaporesection time and prostate volume change were measured.
Results: The 5ARI+ group included 83 patients (45.1%) and the 5ARI- group included 101 patients (54.9%). There were no significant differences in the two groups' preoperative characteristics, postoperative prostate size, thulium laser energy use, or prostate volume reduction rate. However, relative to the 5ARI- group, the 5ARI+ group had a significant shorter total operative time (65.0 min vs. 70.0 min, p=0.013) and a significantly shorter vaporesection time (48.0 min vs. 54.0 min, p=0.014), which resulted in significantly higher vaporesection efficiency in the 5ARI+ group (0.66 mL/min vs. 0.51 mL/min, p<0.001). Both groups exhibit significant improvements in their quality of life score and International Prostate Symptom Score during the 12-month follow-up.
Conclusions: In contrast with our expectations, the preoperative use of 5ARI increased the efficiency of thulium laser surgery for BPH. Thus, it may not be necessary to stop 5ARI treatment before performing thulium laser surgery in this setting.</description><identifier>ISSN: 2466-0493</identifier><identifier>EISSN: 2466-054X</identifier><identifier>DOI: 10.4111/icu.2020.61.1.67</identifier><identifier>PMID: 31942465</identifier><language>eng</language><publisher>SEOUL: Korean Urological Assoc</publisher><subject>5-alpha reductase inhibitors ; 5-alpha Reductase Inhibitors - administration & dosage ; 5-alpha Reductase Inhibitors - adverse effects ; Aged ; Aluminum - therapeutic use ; Fibrosis - chemically induced ; Fibrosis - pathology ; Humans ; Intraoperative Complications - diagnosis ; Intraoperative Complications - etiology ; laser therapy ; Laser Therapy - adverse effects ; Laser Therapy - methods ; Lasers ; Life Sciences & Biomedicine ; Male ; Organ Size ; Original ; Outcome and Process Assessment, Health Care ; Preoperative Period ; Prostate - drug effects ; Prostate - pathology ; Prostate - surgery ; prostatic hyperplasia ; Prostatic Hyperplasia - drug therapy ; Prostatic Hyperplasia - pathology ; Prostatic Hyperplasia - surgery ; Science & Technology ; thulium ; Thulium - therapeutic use ; Urology & Nephrology ; Yttrium - therapeutic use ; 비뇨기과학</subject><ispartof>Investigative and Clinical Urology, 2020, 61(1), , pp.67-74</ispartof><rights>The Korean Urological Association, 2020.</rights><rights>The Korean Urological Association, 2020 2020 The Korean Urological Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>1</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000506022000009</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c496t-634ce8203e7832923956a4dd1b3d51c8b5becebb35e4ed018d05377dff570bf3</citedby><cites>FETCH-LOGICAL-c496t-634ce8203e7832923956a4dd1b3d51c8b5becebb35e4ed018d05377dff570bf3</cites><orcidid>0000-0002-6692-6397 ; 0000-0002-8114-1125 ; 0000-0001-9672-2216 ; 0000-0002-3971-6597 ; 0000-0001-8139-0036 ; 0000-0002-7750-6806 ; 0000-0002-0461-1461 ; 0000-0002-3004-101X ; 0000-0003-0228-0037 ; 0000-0001-8566-3353 ; 0000-0002-0497-6057 ; 0000-0002-8506-9706</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946814/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946814/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2108,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31942465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002548272$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Chung, Jae Seung</creatorcontrib><creatorcontrib>Seo, Won Ik</creatorcontrib><creatorcontrib>Oh, Cheol Kyu</creatorcontrib><creatorcontrib>Kim, Seong Cheol</creatorcontrib><creatorcontrib>Park, Myung Chan</creatorcontrib><creatorcontrib>Park, Sang Hyun</creatorcontrib><creatorcontrib>Yu, Jihyeong</creatorcontrib><creatorcontrib>Lee, Chan Ho</creatorcontrib><creatorcontrib>Kim, Wansuk</creatorcontrib><creatorcontrib>Park, Tae Yong</creatorcontrib><creatorcontrib>Min, Kweon Sik</creatorcontrib><creatorcontrib>Chung, Jae Il</creatorcontrib><title>Effect of 5 alpha-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix (R)) vaporesection for treating benign prostatic hyperplasia</title><title>Investigative and clinical urology</title><addtitle>INVESTIG CLIN UROL</addtitle><addtitle>Investig Clin Urol</addtitle><description>Purpose: Preoperative use of 5 alpha-reductase inhibitors (5ARIS) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH). Thus, we investigated the effects of preoperative 5ARI use in this setting.
Materials and Methods: This retrospective study examined 184 patients who underwent thulium laser surgery for BPH during 2012-2017. Patients were grouped according to their 5ARI use in order to compare their preoperative and intraoperative characteristics and subsequent outcomes. Surgical efficiency was assessed using vaporesection efficiency. The total operation time, vaporesection time and prostate volume change were measured.
Results: The 5ARI+ group included 83 patients (45.1%) and the 5ARI- group included 101 patients (54.9%). There were no significant differences in the two groups' preoperative characteristics, postoperative prostate size, thulium laser energy use, or prostate volume reduction rate. However, relative to the 5ARI- group, the 5ARI+ group had a significant shorter total operative time (65.0 min vs. 70.0 min, p=0.013) and a significantly shorter vaporesection time (48.0 min vs. 54.0 min, p=0.014), which resulted in significantly higher vaporesection efficiency in the 5ARI+ group (0.66 mL/min vs. 0.51 mL/min, p<0.001). Both groups exhibit significant improvements in their quality of life score and International Prostate Symptom Score during the 12-month follow-up.
Conclusions: In contrast with our expectations, the preoperative use of 5ARI increased the efficiency of thulium laser surgery for BPH. Thus, it may not be necessary to stop 5ARI treatment before performing thulium laser surgery in this setting.</description><subject>5-alpha reductase inhibitors</subject><subject>5-alpha Reductase Inhibitors - administration & dosage</subject><subject>5-alpha Reductase Inhibitors - adverse effects</subject><subject>Aged</subject><subject>Aluminum - therapeutic use</subject><subject>Fibrosis - chemically induced</subject><subject>Fibrosis - pathology</subject><subject>Humans</subject><subject>Intraoperative Complications - diagnosis</subject><subject>Intraoperative Complications - etiology</subject><subject>laser therapy</subject><subject>Laser Therapy - adverse effects</subject><subject>Laser Therapy - methods</subject><subject>Lasers</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Organ Size</subject><subject>Original</subject><subject>Outcome and Process Assessment, Health Care</subject><subject>Preoperative Period</subject><subject>Prostate - drug effects</subject><subject>Prostate - pathology</subject><subject>Prostate - surgery</subject><subject>prostatic hyperplasia</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Hyperplasia - surgery</subject><subject>Science & Technology</subject><subject>thulium</subject><subject>Thulium - therapeutic use</subject><subject>Urology & Nephrology</subject><subject>Yttrium - therapeutic use</subject><subject>비뇨기과학</subject><issn>2466-0493</issn><issn>2466-054X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNqNUsGO0zAQjRCIXZW9c0I-UqEWO3achAPSqlqgUiWkVQ_cLNsZN95N7chxCv0dvhSnZSv2hi8zmnnvjT1-WfaW4CUjhHy0elzmOMdLTpZkycsX2XXOOF_ggv14-ZSzml5lN8PwgDEmnJaEVq-zK0pqlvrFdfb7zhjQEXmDCiS7vpWLAM2ooxwAWddaZaMPA_IOxRYQGGO1BaePEyO2Y2fH_adjjCHFhezGvXVTtpPBQUTv7-HgN_ZXSuZzdJC9DzCkcTbJGR9QDCCjdTukwNmdQ33wQ0wVjdpjD6Hv5GDlm-yVkd0AN3_jLNt-uduuvi0237-uV7ebhWY1jwtOmYYqxxTKiuZ1TuuCS9Y0RNGmILpShQINStECGDSYVA0uaFk2xhQlVobOsvlZ1gUjHrUVXtpT3HnxGMTt_XYtOCtrmlY6y9ZnbOPlg-iD3ctwPBFOBR92Qob0jA6EpKoyBWVlxQmDnFVMqaYEaTinmDGctD6ftfpR7aHR4GKQ3TPR5x1n23Sng-A14xVhSQCfBXTa3hDAXLgEi8kpIjlFTE4RnAgieJko7_6deSE8-SIBPpwBP0F5M5y-HC6w5KUCc5zneDrTOqr_R6_s9MPerfzoIv0DJlvetg</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Chung, Jae Seung</creator><creator>Seo, Won Ik</creator><creator>Oh, Cheol Kyu</creator><creator>Kim, Seong Cheol</creator><creator>Park, Myung Chan</creator><creator>Park, Sang Hyun</creator><creator>Yu, Jihyeong</creator><creator>Lee, Chan Ho</creator><creator>Kim, Wansuk</creator><creator>Park, Tae Yong</creator><creator>Min, Kweon Sik</creator><creator>Chung, Jae Il</creator><general>Korean Urological Assoc</general><general>The Korean Urological Association</general><general>Korean Urological Association</general><general>대한비뇨의학회</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-6692-6397</orcidid><orcidid>https://orcid.org/0000-0002-8114-1125</orcidid><orcidid>https://orcid.org/0000-0001-9672-2216</orcidid><orcidid>https://orcid.org/0000-0002-3971-6597</orcidid><orcidid>https://orcid.org/0000-0001-8139-0036</orcidid><orcidid>https://orcid.org/0000-0002-7750-6806</orcidid><orcidid>https://orcid.org/0000-0002-0461-1461</orcidid><orcidid>https://orcid.org/0000-0002-3004-101X</orcidid><orcidid>https://orcid.org/0000-0003-0228-0037</orcidid><orcidid>https://orcid.org/0000-0001-8566-3353</orcidid><orcidid>https://orcid.org/0000-0002-0497-6057</orcidid><orcidid>https://orcid.org/0000-0002-8506-9706</orcidid></search><sort><creationdate>20200101</creationdate><title>Effect of 5 alpha-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix (R)) vaporesection for treating benign prostatic hyperplasia</title><author>Chung, Jae Seung ; Seo, Won Ik ; Oh, Cheol Kyu ; Kim, Seong Cheol ; Park, Myung Chan ; Park, Sang Hyun ; Yu, Jihyeong ; Lee, Chan Ho ; Kim, Wansuk ; Park, Tae Yong ; Min, Kweon Sik ; Chung, Jae Il</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-634ce8203e7832923956a4dd1b3d51c8b5becebb35e4ed018d05377dff570bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>5-alpha reductase inhibitors</topic><topic>5-alpha Reductase Inhibitors - administration & dosage</topic><topic>5-alpha Reductase Inhibitors - adverse effects</topic><topic>Aged</topic><topic>Aluminum - therapeutic use</topic><topic>Fibrosis - chemically induced</topic><topic>Fibrosis - pathology</topic><topic>Humans</topic><topic>Intraoperative Complications - diagnosis</topic><topic>Intraoperative Complications - etiology</topic><topic>laser therapy</topic><topic>Laser Therapy - adverse effects</topic><topic>Laser Therapy - methods</topic><topic>Lasers</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Organ Size</topic><topic>Original</topic><topic>Outcome and Process Assessment, Health Care</topic><topic>Preoperative Period</topic><topic>Prostate - drug effects</topic><topic>Prostate - pathology</topic><topic>Prostate - surgery</topic><topic>prostatic hyperplasia</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Hyperplasia - surgery</topic><topic>Science & Technology</topic><topic>thulium</topic><topic>Thulium - therapeutic use</topic><topic>Urology & Nephrology</topic><topic>Yttrium - therapeutic use</topic><topic>비뇨기과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chung, Jae Seung</creatorcontrib><creatorcontrib>Seo, Won Ik</creatorcontrib><creatorcontrib>Oh, Cheol Kyu</creatorcontrib><creatorcontrib>Kim, Seong Cheol</creatorcontrib><creatorcontrib>Park, Myung Chan</creatorcontrib><creatorcontrib>Park, Sang Hyun</creatorcontrib><creatorcontrib>Yu, Jihyeong</creatorcontrib><creatorcontrib>Lee, Chan Ho</creatorcontrib><creatorcontrib>Kim, Wansuk</creatorcontrib><creatorcontrib>Park, Tae Yong</creatorcontrib><creatorcontrib>Min, Kweon Sik</creatorcontrib><creatorcontrib>Chung, Jae Il</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>Korean Citation Index</collection><jtitle>Investigative and clinical urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chung, Jae Seung</au><au>Seo, Won Ik</au><au>Oh, Cheol Kyu</au><au>Kim, Seong Cheol</au><au>Park, Myung Chan</au><au>Park, Sang Hyun</au><au>Yu, Jihyeong</au><au>Lee, Chan Ho</au><au>Kim, Wansuk</au><au>Park, Tae Yong</au><au>Min, Kweon Sik</au><au>Chung, Jae Il</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of 5 alpha-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix (R)) vaporesection for treating benign prostatic hyperplasia</atitle><jtitle>Investigative and clinical urology</jtitle><stitle>INVESTIG CLIN UROL</stitle><addtitle>Investig Clin Urol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>61</volume><issue>1</issue><spage>67</spage><epage>74</epage><pages>67-74</pages><issn>2466-0493</issn><eissn>2466-054X</eissn><abstract>Purpose: Preoperative use of 5 alpha-reductase inhibitors (5ARIS) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH). Thus, we investigated the effects of preoperative 5ARI use in this setting.
Materials and Methods: This retrospective study examined 184 patients who underwent thulium laser surgery for BPH during 2012-2017. Patients were grouped according to their 5ARI use in order to compare their preoperative and intraoperative characteristics and subsequent outcomes. Surgical efficiency was assessed using vaporesection efficiency. The total operation time, vaporesection time and prostate volume change were measured.
Results: The 5ARI+ group included 83 patients (45.1%) and the 5ARI- group included 101 patients (54.9%). There were no significant differences in the two groups' preoperative characteristics, postoperative prostate size, thulium laser energy use, or prostate volume reduction rate. However, relative to the 5ARI- group, the 5ARI+ group had a significant shorter total operative time (65.0 min vs. 70.0 min, p=0.013) and a significantly shorter vaporesection time (48.0 min vs. 54.0 min, p=0.014), which resulted in significantly higher vaporesection efficiency in the 5ARI+ group (0.66 mL/min vs. 0.51 mL/min, p<0.001). Both groups exhibit significant improvements in their quality of life score and International Prostate Symptom Score during the 12-month follow-up.
Conclusions: In contrast with our expectations, the preoperative use of 5ARI increased the efficiency of thulium laser surgery for BPH. Thus, it may not be necessary to stop 5ARI treatment before performing thulium laser surgery in this setting.</abstract><cop>SEOUL</cop><pub>Korean Urological Assoc</pub><pmid>31942465</pmid><doi>10.4111/icu.2020.61.1.67</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-6692-6397</orcidid><orcidid>https://orcid.org/0000-0002-8114-1125</orcidid><orcidid>https://orcid.org/0000-0001-9672-2216</orcidid><orcidid>https://orcid.org/0000-0002-3971-6597</orcidid><orcidid>https://orcid.org/0000-0001-8139-0036</orcidid><orcidid>https://orcid.org/0000-0002-7750-6806</orcidid><orcidid>https://orcid.org/0000-0002-0461-1461</orcidid><orcidid>https://orcid.org/0000-0002-3004-101X</orcidid><orcidid>https://orcid.org/0000-0003-0228-0037</orcidid><orcidid>https://orcid.org/0000-0001-8566-3353</orcidid><orcidid>https://orcid.org/0000-0002-0497-6057</orcidid><orcidid>https://orcid.org/0000-0002-8506-9706</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2466-0493 |
| ispartof | Investigative and Clinical Urology, 2020, 61(1), , pp.67-74 |
| issn | 2466-0493 2466-054X |
| language | eng |
| recordid | cdi_pubmed_primary_31942465 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; KoreaMed Open Access; PubMed Central |
| subjects | 5-alpha reductase inhibitors 5-alpha Reductase Inhibitors - administration & dosage 5-alpha Reductase Inhibitors - adverse effects Aged Aluminum - therapeutic use Fibrosis - chemically induced Fibrosis - pathology Humans Intraoperative Complications - diagnosis Intraoperative Complications - etiology laser therapy Laser Therapy - adverse effects Laser Therapy - methods Lasers Life Sciences & Biomedicine Male Organ Size Original Outcome and Process Assessment, Health Care Preoperative Period Prostate - drug effects Prostate - pathology Prostate - surgery prostatic hyperplasia Prostatic Hyperplasia - drug therapy Prostatic Hyperplasia - pathology Prostatic Hyperplasia - surgery Science & Technology thulium Thulium - therapeutic use Urology & Nephrology Yttrium - therapeutic use 비뇨기과학 |
| title | Effect of 5 alpha-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix (R)) vaporesection for treating benign prostatic hyperplasia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T09%3A30%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%205%20alpha-reductase%20inhibitors%20on%20the%20efficiency%20of%20thulium:yttrium-aluminium-garnet%20(RevoLix%20(R))%20vaporesection%20for%20treating%20benign%20prostatic%20hyperplasia&rft.jtitle=Investigative%20and%20clinical%20urology&rft.au=Chung,%20Jae%20Seung&rft.date=2020-01-01&rft.volume=61&rft.issue=1&rft.spage=67&rft.epage=74&rft.pages=67-74&rft.issn=2466-0493&rft.eissn=2466-054X&rft_id=info:doi/10.4111/icu.2020.61.1.67&rft_dat=%3Cpubmed_webof%3E31942465%3C/pubmed_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31942465&rft_doaj_id=oai_doaj_org_article_a3b8f53478614e2484bbd7eaf6630440&rfr_iscdi=true |